Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Assessment of V600E Mutation of BRAF Gene and Rate of Cell Proliferation Using Fine-needle Aspirates from Metastatic Melanomas

VITALI SVIATOHA, EDNEIA TANI, MEHRAN GHADERI, REGINA KLEINA and LAMBERT SKOOG
Anticancer Research September 2010, 30 (9) 3267-3272;
VITALI SVIATOHA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vitalijs.svjatoha@karolinska.se
EDNEIA TANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEHRAN GHADERI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
REGINA KLEINA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAMBERT SKOOG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: metastatic melanomas are incurable by systemic treatment and it is therefore of the highest concern to develop new therapeutic regimens. RAF kinases play a key role in the RAS-RAF-MAPK signalling pathway which mediates cellular response to growth signals. An inhibitor of the RAS-RAF-MAPK cascade, sorafenib, has shown promising therapeutic results in treatment of several types of metastatic tumours. It can be hypothesized that metastatic melanomas with activating BRAF mutation may respond to RAF kinase-blocking therapy. The objective of the study was to analyze if the activating BRAF V600E mutation is present in metastatic melanomas. Materials and Methods: Fine-needle aspirates from 44 metastatic melanomas were studied. The V600E mutation in exon 15 of the BRAF gene was selected for genotyping. A Taq-Man MGB biallelic discrimination system was used. Immunocytochemical assessment of the Ki-67 antigen was used to analyze the growth fraction of cells. Results: Nearly 39% of metastatic melanomas had BRAF V600E mutation. Tumours with BRAF V600E mutation had a tendency to have a more aggressive clinical course. The growth fraction showed correlation with tumour progression. This study indicates that the V600E mutation is present in metastatic melanomas and occurs more often in sites without chronic sun exposure. Mutated tumours may have a more aggressive clinical course since such melanomas metastasize at an earlier stage. Determination of the BRAF mutation and the growth fraction of melanomas may add a prognostic value. Conclusion: A fraction of melanoma cases possess an activating BRAF mutation and may benefit from RAF-kinase inhibitor treatment. Future studies are needed to confirm this hypothesis.

  • Fine-needle aspiration
  • BRAF
  • melanoma
  • proliferation

Malignant melanomas make up a heterogeneous group of tumours characterized by particular genetic aberrations depending on their anatomic localization and UV exposure (1). The BRAF gene encodes a serine–threonine-specific protein kinase that acts as an intermediary in the RAS-RAF-mitogen-activated protein kinase (MAPK) signalling pathway. Activation of the MAPK signalling pathway is found in the majority of melanomas, with either somatic mutations of BRAF or, more rarely, NRAS. RAF kinases are signal-integrating enzymes that have the ability to switch tyrosine kinase signalling to serine/threonine phosphorylation and connect growth factor receptors with transcription factors. This pathway involves a cascade of protein kinases that is essential for cellular proliferation and differentiation (2). The most common BRAF mutation, V600E, mimics the phosphorylation, resulting in Ras-independent activation. In a previous study it was shown that blocking of mutant V600E B-Raf inhibited melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo (3). Therefore, the development of RAF-kinase inhibitors for targeted therapy is of interest and might have implication in the treatment of metastatic melanomas which are today considered incurable by available methods (4-6). Agents that specifically target BRAF, such as sorafenib are being actively investigated (7, 8). The aim of the present study was to evaluate the frequency of V600E mutation of BRAF in cells aspirated from metastatic melanomas by fine-needle aspiration and correlate it to clinical and histomorphological properties of the primary tumours, as well as the rate of cell proliferation.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Distribution of mutated and non-mutated cases of metastatic melanoma within groups of different cytological cell types.

Materials and Methods

Forty-four cases of metastatic melanoma were included in the present study. The patients (25 males and 19 females) were between 28 and 90 years of age (median=68.5, mean=66.2 years). The fine-needle aspiration procedure was performed as originally described by Zajicek (9). All patients had been surgically treated for histopathologically verified cutaneous melanoma and were referred to the Division of the Cinical Cytololgy at Karolinska Hospital between 2006 and 2007 for fine-needle aspiration of lesions suspicious for recurrent disease. All cases were stratified into two groups depending on whether the primary tumours were localized on skin with chronic sun exposure/damage (wrists, head and neck) or without it (covered body parts). The metastases were localized as follows: lymph nodes, 28 cases, skin, 11 cases, skeletal muscle, 4 cases and liver, 1 case. One part of the aspirate was used to prepare smears which were subsequently stained with May-Grunwald-Giemsa method and used for cytological diagnosis. Cytologically, the metastases were descriptively classified as predominantly (more than 90% of cells) epithelial, plasma (lymphocyte-like, small cell), spindle and pleomorphic cell type, as well as mixed type (10, 11). From each aspirate, one air-dried and formalin-fixed smear was used for immunostaining with MIB-1 monoclonal antibody to the Ki-67 antigen using a peroxidase-avidin-biotin complex technique as previously described (12). Tumour cells which showed nuclear staining were scored as positive. The second part of the aspirate was suspended in phosphate-buffered saline (pH 7.4) and used for the preparation of the cytospin slides, which were used in diagnostic work-up for staining with antibodies to S-100, vimentin and HMB-45 antigens by a three-step alkaline phosphatase immunostaining procedure as described elsewhere (13). The remaining part of the cell suspension which was not used in the primary immunological work-up was frozen as a cell pellet at −20°C and used for subsequent genotyping of BRAF V600 E mutation. Extraction of the genomic DNA was performed using the Wizard® Genomic DNA Purification Kit (Promega Corporation, Madison, WI, USA). The concentration of DNA was measured using a Nanodrop ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA). A 5′ nuclease assay for allelic discrimination method was used for genotyping of the BRAF mutation. The V600E mutation in exon 15 of the BRAF gene was selected for genotyping. A Taq-Man MGB biallelic discrimination system was used as previously described (14). Probes and oligonucleotides were synthesized in 40 concentrations by Applied Biosystems (Foster City, CA, USA) using the Assay-by-Design ordering system. PCRs were performed on ABI prism Sequence Detection System 7000 (Applied Biosystems). The 25 μl PCR contained 1× of the TaqMan Universal PCR Master Mix, No AmpErase UNG, 1× of the assay probe and primer mix (forward primer CATGAAGACCTCACAGTAAAAATAGGTGAT; reverse primer GGATCCAGACAACTGTTCAAACTGA; VIC MGB probe CCATCGAGATTTCACTGTAG; FAM MGB probe CCATCGAGATTTCTCTGTAG), and 25-50 ng of the sample genomic DNA and was performed on 96-well optical PCR plates.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

HMB-45 immunostaining of metastatic melanoma (fine needle aspirate, cytospin preparation, alkaline phosphatase method, ×400 magnification).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

MIB-1 immunostaining of metastatic melanoma (fine-needle aspirate, smear preparation, immunoperoxidase method, ×200 magnification).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Growth fraction as assessed by MIB-1 in metastatic melanoma with and without BRAF V600E mutation.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Time of developing metastatic disease in patients with melanomas with and without BRAF V600E mutation.

Each genotyping plate contained template controls without DNA, and random samples were run as duplicates to confirm the successful genotyping process. SDS version 2.0 software (Applied Biosystems) was used to analyse real-time PCR data and end-point fluorescence. Genotyping data were exported from SDS software into MS-Excel data sheets for further analysis. All immunochemical reactives were commercially available from Dakopatts (Sweden), Nordic Biosite (Sweden) and Immunotech (France). Data related to the histology of the primary tumours, as well as some clinical data, were available from a computerized file archive system. Statistical analysis was performed using Fisher's exact test, ANOVA and t-test. The level of significance was set at ≤0.05. Statistics and tables were made using Statistica™ software (Statsoft Scandinavia AB, Uppsala, Sween). The study was approved by the local Ethics Committee (protocol number 2005/1331-31/4).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Age distribution in cases of metastatic melanoma with and without BRAF V600E mutation.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Tumour thickness of metastasising primary melanomas grouped by mutated and non-mutated tumours. Growth fraction as assessed by MIB-1 in metastatic melanoma with and without BRAF V600E mutation.

Results

Diagnostic immunostaining with monoclonal antibodies to the S100, vimentin and HMB-45 antigens resulted in distinct cytoplasmic staining (Figure 1). Staining with monoclonal MIB-1 antibody was strictly nuclear (Figure 2). All cases stained positive for S100 and vimentin. A total of 39 cases (90.6%) were positive for HMB-45 as well. In 17 (38.6%) cases, a BRAF V600E mutation was detected. In the group of melanomas in regions with chronic sun exposure (7 cases), only 1 case (14.28%) had a BRAF V600E mutation, whereas in the group without chronic sun exposure (37 cases), 15 cases (40.5%) had this type of somatic mutation (p=0.18820). The fraction of proliferating melanoma cells as measured by MIB-1 staining was slightly higher in the group of metastatic melanoma with mutation compared to that without mutation. The mean percentage of MIB-1-positive cells was 20.7% in non-mutated tumours and 26.2% in tumours with BRAF V600E mutation, respectively (t-value= −1.04374, p=0.302873, Figure 3). The distribution of mutated and non-mutated cases of metastatic melanoma within groups of different cytological cell types is shown in Table I. It can be seen from this Table that the BRAF V600E mutation was not restricted to any cytological type of metastatic melanoma.

Figure 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7.

Clark's invasion level of metastasizing primary melanomas grouped by mutated and non-mutated tumours.

None of the metastases from skeletal muscle or liver revealed the BRAF V600E mutation. In metastases from lymph nodes, 13 cases (46%) had the V600E mutation of the BRAF gene. From 11 cases of skin metastasis, 4 cases (36%) revealed the studied mutation.

Mutated and non-mutated cases showed a different time of development of metastatic disease, with the to metastasis of 25.0 and 14.4 for cases with and without mutation, respectively (t-value=1.45061; p=0.156620, Figure 4). The age distribution was similar in melanomas with and without mutation (Figure 5). The presence of the analysed BRAF V600E mutation in metastatic melanoma was correlated to the histomorphological properties of the corresponding primary tumours such as tumour thickness and Clark's invasion level. The data are summarized in Figure 6 and Figure 7. It can be seen from these Figures that both tumour thickness (t=1.410073; p=0.168802) and Clark's invasion level (t=2.527527; p=0.016990) was lower in primary tumours with BRAF V600E mutation compared to those without mutation. The growth fraction as assessed by the MIB-1 antibody and measured as the percentage of positive cells was compared with respect to histomorphological properties of the primary tumours. The results summarized in Figure 8 and Figure 9 show that the growth fraction of melanomas had an insignificant tendency to be higher with such progression sign as tumour invasion depth (p=0.269188) but not thickness (p=0.592970).

Figure 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 8.

Relationship between growth fraction (assessed by MIB-1) and Clark's invasion depth in melanomas.

Discussion

Malignant melanoma is a highly aggressive malignancy, which is incurable in the majority of patients with available therapy at a metastatic stage (15-17). Thus, development of effective systemic therapy is of utmost interest and importance. Several agents targeted at different points in signalling pathways of cell proliferation and melanoma progression have been tested with very limited success. One of the most important phenomenon in the development of melanoma is the activation of the RAS-RAF-mitogen-activated protein kinase (MAPK) pathway. RAS-regulated kinases, encoded by BRAF, mediate cell growth and malignant transformation (18). Sorafenib is the first oral multi-kinase inhibitor to be developed that targets and inhibits Raf kinases (RAF-1, wild-type BRAF, and BRAF V600E). Sorafenib was recently demonstrated to have an anti tumour effect in metastatic renal cell carcinoma (19) and further investigation is ongoing in several tumour types such as hepatocellular carcinoma (20), leukaemia (21), prostate (22) and colorectal carcinomas (23). If the response to RAF kinase inhibition is dependent on the presence of an activated BRAF protein, it will be necessary to evaluate cases of malignant melanoma for the presence or absence of BRAF mutations.

Figure 9.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 9.

Relationship between growth fraction (assessed by MIB-1) and tumour thickness in melanomas.

In the present study, we analysed BRAF V600E mutation in fine-needle aspirates from metastatic melanomas. Our results show that 38.6% of metastatic melanomas possess this type of somatic mutation and that it is more often present in melanomas arisen in sites without chronic sun-induced damage (40.5% of cases) compared to that of sites chronically exposed to the sun (14.28% of cases). These results are in agreement with previous studies (24). The presence of BRAF V600E mutation was not correlated to any of the cytological cell types. Interestingly, the melanoma cases with a BRAF V600E mutation had a tendency for a shorter time for developing metastatic disease compared to those cases without mutation. Moreover, comparison of histomorphological properties of corresponding primary tumours revealed that melanomas with BRAF V600E tended to acquire metastatic potential at lower Clark's invasion level and lower thickness. This relationship can be seen from Figures 6 and 7. This may indicate that assessing the BRAF V600E mutation in melanomas can add prognostic information to the traditional markers such as tumour thickness and invasion level. Mutated tumours may thus have a more aggressive clinical behaviour because such melanomas metastasize at an earlier stage.

The presence of the BRAF V600E mutation was not confined to any specific localization: 13 out of 28 cases of metastatic tumours from lymph nodes and 4 out of 11 cases from skin metastases showed the mutation. None of the metastases from skeletal muscle or liver revealed the mutation. However, the number of cases in these groups was rather low.

We also analyzed the growth fraction in metastatic melanomas by MIB-1 monoclonal antibody staining. Our results show that advanced melanoma cases have a higher growth fraction than those with a less advanced stage. This observation is in agreement with our previous results (25). Moreover, the present study shows that melanomas with BRAF V600E mutation have a higher proliferating rate. Thus, estimation of growth fraction of malignant melanomas by MIB-1 may have additional prognostic value.

In conclusion, a proportion of melanoma cases possess a BRAF V600E mutation which occurs more often in sites without chronic sun exposure. Cases with BRAF V600E mutation might have more aggressive clinical course. Studies are needed for the evaluation of the effect of treatment with RAF-kinase inhibitors in metastatic melanomas with BRAF mutation.

Acknowledgements

This study was supported by funds from the Cancer Society of Stockholm (Cancerföreningen) in Stockholm and KIRT research-training coopoeration programme between Karolinska Institute and Latvian Medical Academy.

  • Received October 16, 2010.
  • Revision received June 16, 2010.
  • Accepted June 28, 2010.
  • Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Satyamoorthy K,
    2. Herlyn M
    : Cellular and molecular biology of human melanoma. Cancer Biol Ther 1: 14-17, 2002.
    OpenUrlPubMed
  2. ↵
    1. Daum G,
    2. Eisenmann-Tappe I,
    3. Fries HW,
    4. Troppmair J,
    5. Rapp UR
    : The ins and outs of Raf kinases. Trends Biochem Sci 19(11): 474-480, 1994.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Liang S,
    2. Sharma A,
    3. Peng HH,
    4. Robertson G,
    5. Dong C
    : Targeting mutant (V600E) BRAF in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 67: 5814-5820, 2007.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Li N,
    2. Batt D,
    3. Warmuth M
    : B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 8(6): 452-456, 2007.
    OpenUrlPubMed
    1. Kumar R,
    2. Angelini S,
    3. Czene K,
    4. Sauroja I,
    5. Hahka-Kemppinen M,
    6. Pyrhönen S,
    7. Hemminki K
    : BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9(9): 3362-3368, 2003.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chang DZ,
    2. Panageas KS,
    3. Osman I,
    4. Polsky D,
    5. Busam K,
    6. Chapman PB
    : Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2(1): 46, 2004.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Mangiameli DP,
    2. Blansfield JA,
    3. Kachala S,
    4. Lorang D,
    5. Schafer PH,
    6. Muller GW,
    7. Stirling DI,
    8. Libutti SK
    : Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 5: 38, 2007.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Flaherty KT
    : Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 7(5): 617-626, 2007.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wied GL
    1. Zajicek J
    : Aspiration biopsy cytology. Cytology of supra-diaphragmatic organs. In: Monographs in Clinical Cytology. vol 4. Wied GL. Basel: Karger, pp. 1-5, 1974.
    OpenUrl
  9. ↵
    1. Nasiell K,
    2. Tani E,
    3. Skoot L
    : Fine-needle aspiration cytology and immunocytochemistry of metastatic melanoma. Cytopathology 2: 137-147, 1991.
    OpenUrlPubMed
  10. ↵
    1. Barnhill Raymond L.
    1. Barnhill RL
    : Malignant Melanoma. In: Pathology of Melanocytic Nevi and Malignant melanoma. Barnhill Raymond L., Butterworth-Heinemann, 1995.
  11. ↵
    1. Skoog L,
    2. Rutqvist LE,
    3. Wilking N
    : Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 31(2): 139-141, 1992.
    OpenUrlPubMed
  12. ↵
    1. Tani EM,
    2. Christerson B,
    3. Porwit A,
    4. Skoog L
    : Immunocytochemical analysis and cytomorphologic diagnosis on fine-needle aspirates of lymphoproliferative diseases. Acta Cytol 32: 209-215, 1988.
    OpenUrlPubMed
  13. ↵
    1. Livak KJ,
    2. Marmaro J,
    3. Todd JA
    : Towards fully automated genome-wide polymorphism screening. Nat Genet 9: 341-342, 1995.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Buzaid AC
    : Management of metastatic cutaneous melanoma. Oncology (Williston Park) 18(11): 1443-1450, 2004.
    OpenUrlPubMed
    1. Atallah E,
    2. Flaherty L
    : Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6(3): 185-93, 2005.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Dittrich C
    : Targeted therapy – How successful has it been? Eur J Cancer 40: 2016-2021, 2004.
    OpenUrlPubMed
  16. ↵
    1. Mercer K,
    2. Pitchhard C
    : Raf proteins and cancer: B-raf is identified as mutational target. Biochim Biophys Acta 1653: 25-40, 2003.
    OpenUrlPubMed
  17. ↵
    1. Rini BI
    : Sorafenib. Expert Opin Pharmacother 7(4): 453-461, 2006.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lang L
    : FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134(2): 379, 2008.
    OpenUrlPubMed
  19. ↵
    1. Zhang W,
    2. Konopleva M,
    3. Shi YX,
    4. McQueen T,
    5. Harris D,
    6. Ling X,
    7. Estrov Z,
    8. Quintás-Cardama A,
    9. Small D,
    10. Cortes J,
    11. Andreeff M
    : Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3): 184-198, 2008.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Dahut WL,
    2. Scripture C,
    3. Posadas E,
    4. Jain L,
    5. Gulley JL,
    6. Arlen PM,
    7. Wright JJ,
    8. Yu Y,
    9. Cao L,
    10. Steinberg SM,
    11. Aragon-Ching JB,
    12. Venitz J,
    13. Jones E,
    14. Chen CC,
    15. Figg WD
    : A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14(1): 209-214, 2008.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Grávalos C,
    2. Cassinello J,
    3. Fernández-Rañada I,
    4. Holgado E
    : Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 6(10): 691-699, 2007.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Maldonado JL,
    2. Fridlyand J,
    3. Patel H,
    4. Jain AN,
    5. Busam K,
    6. Kageshita T,
    7. Ono T,
    8. Albertson DG,
    9. Pinkel D,
    10. Bastian BC
    : Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24): 1878-1890, 2003.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sviatoha V,
    2. Rundrgen Å,
    3. Tani E,
    4. Hansson J,
    5. Kleina R,
    6. Skoog L
    : Expression of CD40, CD44, BCL-2 antigens and rate of cell proliferation on fine-needle aspirates from metastatic melanoma. Cytopathology 13: 11-21, 2002.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (9)
Anticancer Research
Vol. 30, Issue 9
September 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessment of V600E Mutation of BRAF Gene and Rate of Cell Proliferation Using Fine-needle Aspirates from Metastatic Melanomas
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Assessment of V600E Mutation of BRAF Gene and Rate of Cell Proliferation Using Fine-needle Aspirates from Metastatic Melanomas
VITALI SVIATOHA, EDNEIA TANI, MEHRAN GHADERI, REGINA KLEINA, LAMBERT SKOOG
Anticancer Research Sep 2010, 30 (9) 3267-3272;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Assessment of V600E Mutation of BRAF Gene and Rate of Cell Proliferation Using Fine-needle Aspirates from Metastatic Melanomas
VITALI SVIATOHA, EDNEIA TANI, MEHRAN GHADERI, REGINA KLEINA, LAMBERT SKOOG
Anticancer Research Sep 2010, 30 (9) 3267-3272;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tumor Immunology Visualized in Realtime in In-vivo-like 3-D Gelfoam® Histoculture by Color-coded Imaging
  • The Role of EMP2 in Triple-negative Breast Cancer
  • Role of the Circadian Clock Gene DEC1 in Chemosensitivity and Apoptosis in Colorectal Cancer
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire